MEDI4736 (Durvalumab)(AstraZeneca)은 Advanced Solid Tumors 표적 항체로, Non-Small-Cell Lung Carcinoma NSCLC 영역에서 개발·상용화 중입니다. 작용기전: targeting immune checkpoints - regulatory pathway. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 35.5% (ClinicalTrials.gov NCT02352948). 차별점: uniquely sought to evaluate N2 nodal clearance (N2NC) rates after treatment with chemotherapy and durvalumab.
Advanced Solid Tumors
Non-Small-Cell Lung Carcinoma NSCLC
Active
CAR-T cell and anticancer peptide synergy
vedotin combined with pembrolizumab has displac
humanized patient-derived xenograft mouse model of high-grade serous ovarian cancer for preclinical evaluatio
uniquely sought to evaluate N2 nodal clearance (N2NC) rates after treatment with chemotherapy and durvalumab
targeting immune checkpoints - regulatory pathway
immune-mediated myocarditis, autoimmune myocarditis, pericardial effusion, cardiac tamponade, malignant pericarditis, embolism, and thr
DNA damage response (DDR) mutations and circulating tumor DNA (ctDNA) clearance emerged as promising biomarkers
PD-L1 expression
resistance mechanisms involving EHMT1/2-associated histone methylation, SPINDOC-enhanced PARylation, and ubiquitin-dependent PARP1 stabiliza
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
MEDI4736 (Durvalumab)(AstraZeneca)은 Advanced Solid Tumors 표적 항체로, Non-Small-Cell Lung Carcinoma NSCLC 영역에서 개발·상용화 중입니다. 작용기전: targeting immune checkpoints - regulatory pathway. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 35.5% (ClinicalTrials.gov NCT02352948). 차별점: uniquely sought to evaluate N2 nodal clearance (N2NC) rates after treatment with chemotherapy and durvalumab.
Advanced Solid Tumors
Non-Small-Cell Lung Carcinoma NSCLC
Active
CAR-T cell and anticancer peptide synergy
vedotin combined with pembrolizumab has displac
humanized patient-derived xenograft mouse model of high-grade serous ovarian cancer for preclinical evaluatio
uniquely sought to evaluate N2 nodal clearance (N2NC) rates after treatment with chemotherapy and durvalumab
targeting immune checkpoints - regulatory pathway
immune-mediated myocarditis, autoimmune myocarditis, pericardial effusion, cardiac tamponade, malignant pericarditis, embolism, and thr
DNA damage response (DDR) mutations and circulating tumor DNA (ctDNA) clearance emerged as promising biomarkers
PD-L1 expression
resistance mechanisms involving EHMT1/2-associated histone methylation, SPINDOC-enhanced PARylation, and ubiquitin-dependent PARP1 stabiliza
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.